Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1129Triple Negative Breast Neoplasms 85Neoplasm Metastasis 62Neoplasms 40Breast Neoplasms, Male 20Prostatic Neoplasms 19Carcinoma, Intraductal, Noninfiltrating 19Neutropenia 18HER2-positive Breast Cancer 17Breast Carcinoma In Situ 17Pain 16Carcinoma, Ductal, Breast 16Hot Flashes 15Lung Neoplasms 14Inflammatory Breast Neoplasms 14Breast Diseases 14Brain Neoplasms 14Osteoporosis 13Multiple Myeloma 13Advanced Breast Cancer 13Recurrence 12Ovarian Neoplasms 12Lymphoma, Non-Hodgkin 11Lymphoma, Large B-Cell, Diffuse 11Carcinoma, Ovarian Epithelial 11Testicular Neoplasms 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, Mantle-Cell 10Lymphoma, Large-Cell, Immunoblastic 10Lymphoma, Follicular 10

Interventions

Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants × Breast × Clear all
NCT06846437 2025-03-24

JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer

Shanghai JMT-Bio Inc.

Phase 3 Recruiting
228 enrolled
Breast

Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants

Data powered by HemOnc (CC BY 4.0) Colophon âš¡